Stock listing

NASDAQ:ARTL Artelo Biosciences, Inc. Stock

Home listing (NASDAQ) of Artelo Biosciences, Inc.

Follow Artelo Biosciences, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:ARTL

$2.70 USD -0.04 (-1.5%)

Close on Oct 16, 2026

Since Jul 6, 2026 +147.7% · daily closes, Jul 6, 2026 – Oct 16, 2026, adjusted for splits
Day range
$2.70 – $2.76 USDOct 16, 2026
Volume
12,300 sharesOct 16, 2026
Market value
$1.48M USDAt the close on Oct 16, 2026 · price × 547,774 shares outstanding
Artelo Biosciences, Inc. logo
Ticker
NASDAQ:ARTL
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

Artelo Biosciences Selected for its First-Ever Company Presentation at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potential of its Novel FABP5 Inhibitor Platform

Oct 7, 2026

Artelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical Findings

Sep 23, 2026

Artelo Biosciences Announces ART27.13 Achieved Weight Loss Comparable to Semaglutide as a Monotherapy and Doubled Weight Loss in Combination with Semaglutide in a Nonclinical Model of Obesity

Sep 16, 2026

Artelo Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Sep 8, 2026

Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies

Aug 17, 2026

Artelo Biosciences Provides Business Update and Reports 2026 Second Quarter Financial Results

Aug 13, 2026

New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition

Jul 22, 2026

Artelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting ART26.12 as a Potential First-in-Class New Therapy for Chronic Pain Conditions

Jul 16, 2026

Artelo Biosciences Issues Reminder to Shareholders to Vote in Advance of Annual Meeting on July 17, 2026

Jul 14, 2026

Artelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral Neuropathy

Jul 13, 2026

All Artelo Biosciences, Inc. news

Decks

Artelo Biosciences, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
26 in the last 12 months · 112 in all · newest Oct 7, 2026 · oldest 2019
Decks
4 decks · latest September 2026

Where Artelo Biosciences, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:ARTL · Home listing · This pageNASDAQUnited StatesUSD
BOATS:ARTLBOATSUnited StatesUSD

Log in to ask 6ix AI your own questions about Artelo Biosciences, Inc.